Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
ACS ACS: Cancer Facts & Figures 2001. American Cancer Society, National Home Office, Atlanta, pp 1–44
Adams S, Baum RP, Stuckensen T, et al. (1998) Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25:1255–1260
Bailet JW, Abemayor E, Jabour BA, et al. (1992) Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 102:281–288
Bangerter M, Moog F, Buchmann I, et al. (1998) Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol 9:1117–1122
Burger C, Goerres G, Schoenes S, et al. (2002 a) PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 29:922–927
Burger I, Goerres GW, Von Schulthess GK, et al. (2002b) PET/CT: Diagnostic improvement in recurrent colorectal carcinoma compared to PET alone. Radiology 225:424
Ciernik IF, Dizendorf E, Baumert BG, et al. (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): A feasibility study. International Journal of Radiation Oncology Biology Physics 57:853–863
DeGrado TR, Coleman RE, Wang S, et al. (2001) Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 61:110–117
Delbeke D, Vitola JV, Sandier MP, et al. (1997) Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 38:1196–1201
Dizendorf EV, Baumert BG, von Schulthess GK, et al. (2003) Impact of whole-body F-18-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44:24–29
Falk PM, Gupta NC, Thorson AG, et al. (1994) Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 37:153–156
Flamen P, Stroobants S, Van Cutsem E, et al. (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 17:894–901
Goerres GW, Schmid DT, von Schulthess GK, et al. (2003) FDG PET/CT improves the confidence of anatomic assignment of cancer lesions in the head and neck: a comparison with FDG PET and contrast-enhanced CT. J Nucl Med 44:417–zzz
Goldberg RM, Fleming TR, Tangen CM, et al. (1998) Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 129:27–35
Gupta NC, Maloof J, Gunel E (1996) Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37:943–948
Hany TF, Steinert HC, Goerres GW, et al. (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225:575–581
Higashi K, Ueda Y, Seki H, et al. (1998) Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39:1016–1020
Huang SC, Phelps ME, Hoffman EJ, et al. (1980) Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 238:E69–E82
Jaszczak RJ, Hoffman ED (1995) Positron Emission Tomography (PET): scatter and attenuation, in Wagner HN, Szabo Z, Buchanan JW (eds): Principles of nuclear medicine, 2nd edn. WB Saunders, Philadelphia
Jerusalem G, Beguin Y, Fassotte MF, et al. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85:613–618
Jerusalem G, Beguin Y, Fassotte MF, et al. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429–433
Jerusalem G, Hustinx R, Beguin Y, et al. (2002) The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 13:227–234
Kau RJ, Alexiou C, Laubenbacher C, et al. (1999) Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 125:1322–1328
Kinahan PE, Townsend DW, Beyer T, et al. (1998) Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25:2046–2053
Lardinois D, Weder W, Hany TF, et al. (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507
Moog F, Bangerter M, Kotzerke J, et al. (1998a) 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 16:603–609
Moog F, Bangerter M, Diederichs CG, et al. (1998b) Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 206:475–481
Moog F, Bangerter M, Diederichs CG, et al. (1997) Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795–800
Namdar M, Hany TF, Burger C, et al. (2003) Combined computed tomography-angiogram and positron emission tomography perfusion Imaging for assessment of coronary artery disease in a novel PET/CT: a pilot feasibility study. J Am Coll Cardiol 41:439A
Patz EF, Jr, Lowe VJ, Hoffman JM, et al. (1993) Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487–490
Patz EF, Jr, Lowe VJ, Hoffman JM, et al. (1994) Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. Radiology 191:379–382
Phelps ME (1981) Positron computed tomography studies of cerebral glucose metabolism in man: theory and application in nuclear medicine. Semin Nucl Med 11:32–49
Ruers TJ, Langenhoff BS, Neeleman N, et al. (2002) Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorec-tal liver metastases: a prospective study. J Clin Oncol 20:388–395
Schaefer NG, Hany TF, Taverna C, et al. (2003) FDG PET/CT versus contrast enhanced CT in aggressive non-Hodgkin lymphoma and Hodgkin’s disease. J Nucl Med 44:272
Stokkel MP, Moons KG, ten Broek FW, et al. (1999) 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer. Cancer 86:2370–2377
Stumpe KD, Urbinelli M, Steinert HC, et al. (1998) Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 25:721–728
Webb WR, Gatsonis C, Zerhouni EA, et al. (1991) CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 178:705–713
Webb WR, Sarin M, Zerhouni EA, et al. (1993) Interobserver variability in CT and MR staging of lung cancer. J Comput Assist Tomogr 17:841–846
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hany, T.F., von Schulthess, G.K. (2005). PET/CT: Combining Function and Morphology. In: Bogdanov, A.A., Licha, K. (eds) Molecular Imaging. Ernst Schering Research Foundation Workshop, vol 49. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26809-X_5
Download citation
DOI: https://doi.org/10.1007/3-540-26809-X_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-21021-4
Online ISBN: 978-3-540-26809-3
eBook Packages: MedicineMedicine (R0)